



Eastland Medical  
Systems LTD

## ASX Release

### **ArTiMist™ listed as one of the 5 most promising drugs in Phase III trials.**

Eastland is pleased to announce that one of the world's leading Pharmaceutical Intelligence groups, Thomson Reuters, has listed Eastland's lead project ArTiMist™ as being one of the 5 most promising drugs to enter into Phase III trials. The whole article can be viewed on the Thomson Reuters website:

[thomsonreuters.com/content/science/pdf/ls/pharma\\_matters/the\\_ones\\_to\\_watch.pdf](http://thomsonreuters.com/content/science/pdf/ls/pharma_matters/the_ones_to_watch.pdf)

Eastland's CEO Stephen Carter stated that "the ArTiMist™ project is World Class and we are pleased to see that a group as prominent as Thomson Reuters acknowledges the potential importance of the ArTiMist™ project in the global fight against malaria."

Note: The article refers to Star Medical, a wholly owned subsidiary of Eastland Medical Systems Ltd. Star Medical has now been deregistered. All of Star Medicals assets and undertakings were absorbed into Eastland Medical Systems Ltd.

**Further information:**

Stephen Carter  
Chief Executive Officer  
Director  
Eastland Medical Systems Ltd  
Tel: +61 8 6142 5555  
[sjcarter@eastlandmedical.com.au](mailto:sjcarter@eastlandmedical.com.au)